Breaking News

BMS, GRAIL in Precision Medicine Pact

BMS investment aims to advance pipeline with highly sensitive blood tests that detect cancer early

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb Co. has made an equity investment and plans to enter a research collaboration with GRAIL Inc., a life sciences company dedicated to detecting cancer early. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early stages to enable earlier intervention with targeted therapies by combining high intensity cancer DNA sequencing, computer science and large clinical studies into a diagnostic platform. BMS will gain early access to GRAIL’s clinical tria...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters